Toxicity and mainly dysphagia have increased in head and neck cancers as chemoradiation indications have risen over the last decade, leading to a significant loss of quality of life for patients. Recently, many retrospective studies and two evidence-based and systematic reviews on strategies to reduce radiation-induced dysphagia have suggested a trend toward benefit for a preventive swallowing exercise program. The main hypothesis of this study is that an early active swallowing therapy can improve the Quality of Life (QoL) of patients treated by radiotherapy for head and neck cancer. The study will be a randomized controlled, open-label, multicentric phase III clinical trial comparing early active swallowing therapy versus non specific swallowing management (usual care).
Patients in both groups will receive dietary and postural advice from the treating physician. Patients in the experimental group will be treated with an early active swallowing therapy including a consultation with a speech and language therapist twice a week and a detailed program of swallowing auto-exercises twice a day, from the start to one month after the end of radiotherapy. All speech therapists will be given precise guidelines based on the current state of the art and knowledge. All patients will be analyzed in intent-to-treat. Two ancillary studies will complete this global concept of the evaluation and prediction of severe alteration of Quality of Life (QoL) and Dysphagia. 1. A first study will evaluate videoradioscopy. Its objectives are to evaluate the ability of videoradioscopy at 3 months to predict poor QoL at 6 and 12 months, to identify videoradioscopic predictors of severe dysphagia, asymptomatic aspirations, cricopharyngeal stenoses and active swallowing rehabilitation efficiency. Each patient of both arms of the main study will undergo a videoradioscopy before the beginning of the radiation delivery (baseline evaluation), and at 3 and at 12 months. Data analysis will be centralized and will concern: APS (Aspiration and Penetration Scale) score, residue, Defective Laryngeal elevation, pharyngoesophageal sphincter dysfunction. Data will be correlated to the parameters of the main study in order to establish predictive models. 2. A second ancillary study will evaluate the dose-volume histograms of radiotherapy. The objectives are to identify predictors of dysphagia and of active swallowing rehabilitation efficiency, and to establish "2D" and "3D" predictive models of dysphagia. Imaging and dosimetric data (IMRT (Intensity Modified RadioTherapy) planning) and dose-volume histogram will be collected from the patients of the main clinical trial. Analysis will be centralized. Data will be correlated to the parameters of the main study in order to establish predictive models.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
183
Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
Brest University Hospital
Brest, France
Caen University Hospital
Caen, France
Centre François Baclesse
Caen, France
Clermont-Ferrand University Hospital
Clermont-Ferrand, France
Le Mans Hospital
Le Mans, France
Lille University Hospital
Lille, France
Bretagne Sud Hospital
Lorient, France
Lyon University Hospital
Lyon, France
Marseille University Hospital
Marseille, France
Centre Alexis Vautrin
Nancy, France
...and 11 more locations
Proportion of patients experiencing a clinically relevant improvement defined as a decrease of at least 10 points of the score HNSW ( 6 months after radiotherapy compared with the score before radiotherapy
HNSW = Head and Neck Swallowing Questionnaire
Time frame: 6 months after radiotherapy
EORTC QLQ-C30 score
EORTC QLQ = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
EORTC H&N35 score
EORTC H\&N = European Organisation for Research and Treatment of Cancer Head and Neck questionnaire
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
MFI-20 score
MFI = Multidimensional Fatigue Inventory
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
Body Mass index (BMI)
in kg/m\^2
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
Functional Oral Intake Scale (FOIS)
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
Overall duration of enteral nutrition
Time frame: 12 months after radiotherapy
Total treatment duration
Time frame: 12 months after radiotherapy
Number of treatment interruptions
Time frame: 12 months after radiotherapy
Number of patients with adverse events
Time frame: End of radiotherapy (an average of 2 months after baseline), 1, 3, 6 and 12 months after radiotherapy
Swallowing specific Quality of Life (SWAL-QOL) score
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
Number of patients with aspiration and penetration determined by APS (Aspiration and Penetration Scale) scoring
Time frame: Baseline, 3, 6 and 12 months after radiotherapy
Rate of global survival
Time frame: 12 months after radiotherapy
Rate of survival without recurrence
Time frame: 12 months after radiotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.